Jason is a Postdoctoral Scholar and Weill Neurohub Fellow. He earned his MD and PhD from West Virginia University. His current research focuses on several key areas of antibody engineering, including the development of monoclonal antibodies to prevent prenatal opioid exposure and to counter emerging drugs of abuse, such as xylazine. He is also working on engineering antibodies with modified Fc properties. Outside of lab, Jason enjoys cycling, snowboarding, and rooting for the Seahawks. 
Fatima A Hamid obtained her B.s in pharmacy from University of Khartoum, Sudan, and M.s in toxicology from Università degli Studi di Milano in Italy in 2019. Her research focuses on using nanoparticles-based carriers and novel adjuvants targeting Toll-like receptor (TLRs) to enhance the efficacy of anti-opioids conjugate vaccines. Moreover, dissecting the molecular and cellular mechanisms associated with this enhancement to provide a blueprint for rational vaccine design. In her spare time, Fatima loves to travel to new places, and try new food.
Joseph obtained his Ph.D in Molecular and Cellular Pharmacology from the University of Wisconsin in 2023. He completed his training at Wisconsin in the lab of Dr. Aaron LeBeau, Ph.D. focusing on the development of single domain antibodies as novel theranostic platform technologies for metastatic Prostate Cancer. His research interests surround the development and engineering of non-canonical antibodies derived from species such as sharks and llamas. Joseph joined the Pravetoni lab May 2024 and is currently developing non-canonical antibodies for the treatment of overdose related to ultra-potent synthetic opioids. In his free time, Joseph enjoys being a cat dad, searching for classic vinyls, and finding new coffee shops.